Results of Macitentan in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension ― A Prospective, Multicenter, Open-Label, Single-Arm, Phase 3 Study ―
Open Access
- 9 July 2021
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 3 (7), 405-413
- https://doi.org/10.1253/circrep.cr-21-0034
Abstract
Background:Macitentan, an endothelin-receptor antagonist, is approved in Japan for the treatment of pulmonary arterial hypertension (PAH). This study evaluated the use of macitentan for chronic thromboembolic pulmonary hypertension (CTEPH) in Japanese patients. Methods and Results:This open-label single-arm Phase 3 study evaluated the efficacy and safety of oral macitentan 10 mg (once daily) in Japanese CTEPH patients. The study was prematurely discontinued due to the sponsor’s decision to not develop macitentan 10 mg further for the indication of CTEPH (unrelated to safety concerns). Of the 9 patients enrolled in the study, 4 completed 24 weeks of treatment. The mean (±SD) ratio of pulmonary vascular resistance (PVR) at Week 16 to baseline was 71.9±34.3%. The mean (±SD) decreases in PVR and the PVR index (PVRI) from baseline to Week 16 were 181.4±243.9 dyn·s/cm5and 280.6±366.0 dyn·s·m2/cm5, respectively. The mean (±SD) increase in the 6-min walk distance from baseline to Week 24 was 44.3±46.8 m. All treatment-emergent adverse events (TEAEs) were mild or moderate in severity, except for 1 serious TEAE of angioplasty reported in 1/9 patients that was severe in intensity. Conclusions:Definite conclusions regarding the efficacy of macitentan 10 mg in Japanese patients with CTEPH cannot be drawn because of premature study discontinuation. No safety concerns were observed, and the safety profile was consistent with previously reported studies in CTEPH and PAH patients.Keywords
This publication has 30 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle CellsPLOS ONE, 2012
- Endothelin receptor antagonists for the treatment of pulmonary arterial hypertensionExpert Opinion on Pharmacotherapy, 2011
- Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registryThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Role of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial HypertensionAnnual Review of Medicine, 2009
- Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled TrialJournal of the American College of Cardiology, 2008
- Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertensionJournal of Thrombosis and Haemostasis, 2007
- Assessment of Operability in Chronic Thromboembolic Pulmonary HypertensionProceedings of the American Thoracic Society, 2006
- Chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2004
- PULMONARY VASCULAR REMODELING DISTAL TO PULMONARY ARTERY LIGATION IS ACCOMPANIED BY UPREGULATION OF ENDOTHELIN RECEPTORS AND NITRIC OXIDE SYNTHASEExperimental Lung Research, 2000